US Foods Raises $1B Through Debt Offering

US Foods Holding Corp (NYSE: USFD) has commenced a private offering of $1.0 billion aggregate principal amount of notes, consisting of senior unsecured notes due 2028 and senior unsecured notes due 2032 by its 

US Foods Holding Corp (NYSE:USFD) has commenced a private offering of $1.0 billion aggregate principal amount of notes, consisting of senior unsecured notes due 2028 and senior unsecured notes due 2032 by its wholly-owned subsidiary, US Foods Inc.

US Foods intends to use the net proceeds of the offering, together with cash on hand, to fund the redemption of its outstanding 6.250% senior secured notes due 2025.

The company held $379 million in cash and equivalents as of July 1, 2023.

In its recent quarter report, US Foods revised its FY23 outlook for adjusted EPS to $2.55-$2.65 from $2.45 – $2.65, against the consensus of $2.62.

Net Debt at the end of the second quarter was $4.4 billion. Net Debt to Adjusted EBITDA ratio was 3.0x at the end of the second quarter of fiscal 2023, compared to 3.5x at the end of fiscal 2022 and 4.2x at the end of Q2 2022.

Price Action: USFD shares are trading lower by 0.62% at $39.22 on the last check Monday.

Total
0
Shares
Related Posts
Read More

GSE Solutions Wins $1.5M Contract To Provide Engineering Services And Staffing Support To U.S. Uranium Enrichment Provider

GSE Solutions ("GSE Systems, Inc." or "GSE") (NASDAQ: GVP), a leader in advanced engineering and workforce solutions that supports the future of clean-energy production and decarbonization initiatives of the nuclear power industry, today announced a combined-capabilities contract valued at approximately $1.5M for engineering a

GVP

Read More

Cellectar Biosciences Expands A New Licensing Agreement With The Wisconsin Alumni Research Foundation For Intellectual Property That Was The Result Of Collaborative Research With Iopofosine I 131 In Pediatric Cancers

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced a new licensing

CLRB